How are advances in ALL genomics informing new treatment approaches?

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Charles Mullighan, St. Jude Children's Research Hospital, Memphis, US. We asked, How are advances in ALL genomics informing new treatment approaches?


Mullighan begins by highlighting the impact advances in genomics have had on ALL diagnosis and treatment, such as RNA sequencing. He goes into more detail about subtypes and the shortcomings of a gene panel approach for ALL. Mullighan discusses the benefits for patients, such as improved risk stratification, and optimization of novel and conventional therapies. Finally, he highlights the value in tracking clonal mutations and outlines the role of genomics in T-ALL.


Hosted on Acast. See acast.com/privacy for more information.

More from ALL Hub

  1. 12:40Global socioeconomic disparities in ALL: toxicity in Brazil and GuatemalaOct 10, 2023
  2. 22:50Global socioeconomic disparities in ALL: treatment challenges in Brazil and GuatemalaOct 10, 2023
  3. 18:24Global socioeconomic disparities in ALL: diagnostic challenges in Brazil and GuatemalaOct 10, 2023
  4. 18:24Global socioeconomic disparities in ALL: Diagnostic challengesSep 07, 2023
  5. 12:40Global socioeconomic disparities in ALL: toxicitySep 07, 2023
  6. 22:50Global socioeconomic disparities in ALL: treatment challengesSep 05, 2023
  7. 12:36What is the cellular origin of ALL?Jun 28, 2022
  8. 09:19How are advances in ALL genomics informing new treatment approaches?Dec 22, 2021
  9. 06:40How does MRD guide therapeutic decisions in ALL?Sep 22, 2021
  10. 28:27What is new for CAR T-cell therapy for adult patients with ALL?Apr 07, 2021